Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT07566988
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
Sponsor: Novartis Pharmaceuticals
View on ClinicalTrials.gov
Summary
The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.
Official title: Comparative Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice: A Retrospective Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
2604
Start Date
2024-10-25
Completion Date
2025-04-30
Last Updated
2026-05-11
Healthy Volunteers
No
Conditions
Locations (1)
Novartis
East Hanover, New Jersey, United States